Leiden University Medical Center

CCC Helps Establish Leiden Institute for FAIR and Equitable Science (LIFES) as a Founding Member

Retrieved on: 
星期三, 六月 5, 2024
Data Management, Technology, Professional Services, Publishing, Communications, Other Technology, Research, Data Analytics, Artificial Intelligence, Legal, Science, Interoperability, Ecosystem, Organization, TNO, LUMC, Accessibility, GO, CCC, Metadata, Information services, Growth, Leiden University Medical Center, University, Sage, AI, Machine learning, DEI, Naturalis Biodiversity Center, Partnership, Findability, FAIR, Knowledge, Drug development

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announced its collaboration with key industry stakeholders to launch the Leiden Institute for FAIR and Equitable Science (LIFES).

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announced its collaboration with key industry stakeholders to launch the Leiden Institute for FAIR and Equitable Science (LIFES).
  • Along with CCC, the founding partners of LIFES include the GO FAIR Foundation , FAIRscholar, HINQ , Leiden University Medical Center (LUMC), Leiden Academic Centre for Drug Research (LACDR), Naturalis Biodiversity Center , Roche Nederland B.V ., Sage , TNO , and the University of Twente (UT).
  • LIFES will foster collaborations to bridge the deficiencies in current technical capabilities and research methodologies that present unnecessary barriers to equitable data visiting.
  • To learn more about CCC and FAIR data, visit CCC’s resource library: https://www.copyright.com/tag/fair-data/ .

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

Retrieved on: 
星期一, 六月 3, 2024
Biotechnology, Pharmaceutical, Health, Oncology, NDA, ITT, ASCO, RECIST, Manuscript, Patient, Annual general meeting, TGCT, Cancer, IRR, Clinical study design, Safety, Tenosynovial giant cell tumor, Society, Week, Leiden University Medical Center, Cholestasis, Part 1, Part, Pharmaceutical industry

The article titled “Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a randomised phase 3 trial” is now available online and will be published in a future print issue of The Lancet.

Key Points: 
  • The article titled “Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a randomised phase 3 trial” is now available online and will be published in a future print issue of The Lancet.
  • Presentation details are as follows:
    Title: Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.
  • The open-label Part 2 portion of MOTION, in which patients from both the vimseltinib and placebo arms receive treatment with vimseltinib, remains ongoing.
  • Title: DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.

Sapreme Appoints CEO, BoD Chair and SAB to Advance Development of Next-Generation RNA Therapeutics for Genetically Driven Diseases

Retrieved on: 
星期二, 五月 28, 2024
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, MSD, Medical laboratory, University College Dublin, Self-publishing, Whitehead Institute, Drug development, Molecular medicine, Vaccine, Genetics, RNA, Therapy, Infection, ALS, Free University, Saponin, MIT, MD, MB, Organon, Master of Science, Clinical chemistry, LUMC, Protein, Asos, Duchenne muscular dystrophy, Medicinal chemistry, Psychiatry, Neurology, Complex conjugate, EAN, SAB, Peptide, Damme, Patient, Doctor of Philosophy, Organization, Free University of Berlin, University, Schering-Plough, Leiden University, DMD, Growth, Spacecraft, Cancer, Leiden University Medical Center, Pharmaceutical industry

Sapreme , a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD).

Key Points: 
  • Sapreme , a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD).
  • Before joining Sapreme, he was CEO of Byondis (formerly Synthon Biopharmaceuticals), a clinical-stage biopharmaceutical company developing Antibody-Drug Conjugates (ADCs) targeting intractable cancers and auto-immune diseases.
  • During his time at Byondis, Dr. Timmers also served as Chief Scientific Officer, guiding the company’s clinical strategies and growth.
  • I look forward to working with the team at Sapreme to further advance this innovative platform and accelerate our pipeline of RNA therapeutic candidates addressing a range of genetically driven diseases,” said Marco Timmers, Chief Executive Officer of Sapreme.

MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts

Retrieved on: 
星期四, 三月 7, 2024
Therapy, CNRS, Target, Newcastle University, Facial muscles, Biotechnology, Professor, Teaching hospital, SAB, Neuromuscular disease, Ageing, Leiden University Medical Center, HD, DMD, Duchenne muscular dystrophy, Inflammation, LUMC, Mitochondrion, Gene therapy, Scientific method, Genetics, Knowledge, Leibniz Association, Publication, Translational research, Respiratory disease, Research, COPD, Pharmaceutical industry

OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.

Key Points: 
  • OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.
  • Dr. Jon Rees, Chief Executive Officer of MitoRx, said, “We are thrilled to welcome Dr.
  • Le Guiner, Dr. Filipovic, Professor Hansbro, and Professor Aartsma-Rus, to our Scientific Advisory Board.
  • She has a visiting professorship at the John Walton Muscular Dystrophy Research Center at the UK’s Newcastle University.

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
星期五, 二月 23, 2024
Methylation, Dysbiosis, Culture, Penn Center, Health, Bacteria, University, Subtypes of HIV, Life Length, Wistar Institute, Bangladesh Technical Education Board, Ileum, Infection, NIH, AIDS, Glass, Metabolomics, Nucleotide, DSM-IV codes, Biomedical Research, HIV/AIDS research, Wistar, University of Pittsburgh, DNA, Immune system, National Institutes of Health, Leiden University Medical Center, Weill Cornell Medicine, Hannum, Research, Inflammation, Blood, Ageing, Cancer, Cell biology, Microbiome, Rush University, HIV, DNA methylation, Vaccine

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD

Retrieved on: 
星期四, 十一月 30, 2023
NGS, SMCHD1, OGM, Facioscapulohumeral muscular dystrophy, SAN, FSHD, LDT, Mosaic, Laboratory, Leiden University Medical Center, Bombay Hospital, Diagnosis

The study authors assessed the yield of OGM for diagnosing FSHD1 and the ability of next generation sequencing (NGS) to be used as a reflex test to identify FSHD2.

Key Points: 
  • The study authors assessed the yield of OGM for diagnosing FSHD1 and the ability of next generation sequencing (NGS) to be used as a reflex test to identify FSHD2.
  • The study, which included 547 cases with a clinical suspicion of FSHD, used an algorithm that utilized OGM to identify the FSHD haplotype and quantitate the number of D4Z4 repeats found on chromosome 4.
  • “Bionano Laboratories has developed a powerful menu of OGM-based LDTs, including one LDT for FSHD1 diagnosis.
  • We are pleased to see this prestigious group of researchers’ findings from the largest FSHD study to date utilizing OGM.

Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT

Retrieved on: 
星期一, 十月 30, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Week, IRR, TGCT, Neoplasm, ITT, CSF1R, Leiden University Medical Center, Caregiver, Medicine, Stiffness, ORR, RECIST, Part, Safety, Cancer, Patient, Pharmaceutical industry

“TGCT has a significant negative impact on the daily life of patients who face substantial pain, stiffness, and impaired mobility.

Key Points: 
  • “TGCT has a significant negative impact on the daily life of patients who face substantial pain, stiffness, and impaired mobility.
  • Success across both the primary and all key secondary endpoints in MOTION underscores vimseltinib’s ability to help TGCT patients feel and function better.
  • “The totality of data shown today demonstrate the potential for vimseltinib to offer a new and differentiated treatment option for patients with TGCT.
  • The open-label Part 2 portion of MOTION, in which patients from both the vimseltinib and placebo arms receive treatment with vimseltinib, remains ongoing.

Smart Immune Showcases Data and Presentations at ESGCT

Retrieved on: 
星期四, 十月 12, 2023
Congress, Doctor of Philosophy, Leiden University Medical Center, CSO, Sickle cell disease, MD, Cell, Gene, Experiment, University, CEST, Entrepreneurship, Immune system, ESGCT, PID, EIC, European Society of Gene and Cell Therapy, Vaccine

PARIS, France, 12 October 2023 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell progenitor therapy platform to fully and rapidly re-arm the immune system, announced today a series of activities in and around the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress being held in Brussels, Belgium from October 24-27, 2023.

Key Points: 
  • PARIS, France, 12 October 2023 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell progenitor therapy platform to fully and rapidly re-arm the immune system, announced today a series of activities in and around the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress being held in Brussels, Belgium from October 24-27, 2023.
  • Attended by Smart Immune’s Chief Executive Officer Karine Rossignol and other members of Smart Immune’s team.
  • Karine Rossignol, Chief Executive Officer of Smart Immune, said: “We are excited to be at the ESGCT congress.
  • Our team will be attending a range of activities including an oral presentation by our CSO, and our participation in the EIC Cell and Gene Therapy symposium as one of the EIC accelerator laureates.”
    If you would like to meet with the Smart Immune team during the congress, or at any other time, please contact: [email protected]

OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position

Retrieved on: 
星期四, 六月 15, 2023
Envision, Science, Data science, Anvar, Doctor of Philosophy, Acquisition, Patient, Master of Science, Pleasure, Artificial intelligence, Brunel University London, Faculty, AI, Health, Leiden University Medical Center, Computational biology, Leiden University, Medical device, Medicine

PHILADELPHIA, PA, June 15, 2023 - (ACN Newswire) - OKRA.ai, an Envision Pharma Group (Envision) company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry.

Key Points: 
  • PHILADELPHIA, PA, June 15, 2023 - (ACN Newswire) - OKRA.ai, an Envision Pharma Group (Envision) company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry.
  • "I am excited about continuing the innovative collaboration between Envision and OKRA.ai along with Yahya as a senior leader as it further solidifies our Envision commitment to the expansion of OKRA.ai and leadership in the AI and technical space," shares Meg Heim, CEO of Envision Pharma Group.
  • His role has now expanded to cover AI insights and scientific expertise across the entire Envision organization following our recent acquisition.
  • I look forward to working with him in driving AI innovation and propelling Envision to new heights."

Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert

Retrieved on: 
星期五, 七月 28, 2023
Xylazine, University, Naloxone, Leiden University Medical Center, Tennessee Bureau of Investigation, Opioid overdose, Research, Doctor of Philosophy, ADMP, Parent, Trial of the century, Incidence, MD, Drug, Poisoning, Hypoventilation, Patient, Hearing, SAN, FDA, LUMC, Regulation of tobacco by the U.S. Food and Drug Administration, Fentanyl, Food, Anesthesiology, Pharmaceutical industry, Anesthesia, Adamis

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.

Key Points: 
  • SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.
  • The funding will support the work of Albert Dahan, MD, PhD, a world expert on opioid-induced respiratory depression (opioid overdose) and professor of anesthesiology at the University.
  • Dr. Dahan has been working with the FDA since 2020 to understand better methods of reversing fentanyl overdoses.
  • Samuel P. Chapman, Director of Parents for Safer Children, stated, “Prescription strength ZIMHI is the best remedy available for opioid overdose.